NovoCure annual ebitda margin
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
NovoCure EBITDA Margin Growth & History (NVCR)
NovoCure's ebitda margin was −21.23% for fiscal 2025.
View full NovoCure company overviewNovoCure annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −21.23% | +5.08 pp |
| 2024 | 2024-12-31 | −26.31% | +17.25 pp |
| 2023 | 2023-12-31 | −43.57% | −28.90 pp |
| 2022 | 2022-12-31 | −14.67% | −8.30 pp |
| 2021 | 2021-12-31 | −6.37% | −14.37 pp |
| 2020 | 2020-12-31 | 8.00% | +5.85 pp |
| 2019 | 2019-12-31 | 2.15% | +12.09 pp |
| 2018 | 2018-12-31 | −9.94% | +7.94 pp |
| 2017 | 2017-12-31 | −17.88% | +114.43 pp |
| 2016 | 2016-12-31 | −132.31% | +172.48 pp |
| 2015 | 2015-12-31 | −304.78% | +200.02 pp |
| 2014 | 2014-12-31 | −504.80% | +105.71 pp |
| 2013 | 2013-12-31 | −610.51% | — |
NovoCure quarterly ebitda margin
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −3.41% | +19.31 pp |
| Q1 2026 | 2026-03-31 | −36.37% | −14.08 pp |
| Q4 2025 | 2025-12-31 | −20.75% | +16.58 pp |
| Q3 2025 | 2025-09-30 | −19.35% | −0.25 pp |
| Q2 2025 | 2025-06-30 | −22.72% | −2.28 pp |
| Q1 2025 | 2025-03-31 | −22.28% | +5.66 pp |
| Q4 2024 | 2024-12-31 | −37.33% | −0.71 pp |
| Q3 2024 | 2024-09-30 | −19.11% | +24.44 pp |
| Q2 2024 | 2024-06-30 | −20.43% | +27.12 pp |
| Q1 2024 | 2024-03-31 | −27.95% | +19.14 pp |
| Q4 2023 | 2023-12-31 | −36.62% | −5.26 pp |
| Q3 2023 | 2023-09-30 | −43.55% | −26.79 pp |
| Q2 2023 | 2023-06-30 | −47.55% | −34.44 pp |
| Q1 2023 | 2023-03-31 | −47.08% | −48.39 pp |
| Q4 2022 | 2022-12-31 | −31.36% | −15.80 pp |
| Q3 2022 | 2022-09-30 | −16.76% | −12.40 pp |
| Q2 2022 | 2022-06-30 | −13.11% | −5.76 pp |
| Q1 2022 | 2022-03-31 | 1.31% | −0.38 pp |
| Q4 2021 | 2021-12-31 | −15.56% | −25.68 pp |
| Q3 2021 | 2021-09-30 | −4.35% | −17.33 pp |
| Q2 2021 | 2021-06-30 | −7.35% | −15.35 pp |
| Q1 2021 | 2021-03-31 | 1.69% | +3.16 pp |
| Q4 2020 | 2020-12-31 | 10.12% | +7.48 pp |
| Q3 2020 | 2020-09-30 | 12.97% | +6.69 pp |
| Q2 2020 | 2020-06-30 | 8.00% | +4.16 pp |
| Q1 2020 | 2020-03-31 | −1.47% | +4.25 pp |
| Q4 2019 | 2019-12-31 | 2.64% | +11.91 pp |
| Q3 2019 | 2019-09-30 | 6.29% | +10.82 pp |
| Q2 2019 | 2019-06-30 | 3.84% | +11.64 pp |
| Q1 2019 | 2019-03-31 | −5.71% | +14.38 pp |
| Q4 2018 | 2018-12-31 | −9.27% | −4.89 pp |
| Q3 2018 | 2018-09-30 | −4.53% | +3.18 pp |
| Q2 2018 | 2018-06-30 | −7.80% | +27.95 pp |
| Q1 2018 | 2018-03-31 | −20.09% | +13.49 pp |
| Q4 2017 | 2017-12-31 | −4.38% | +49.47 pp |
| Q3 2017 | 2017-09-30 | −7.72% | +115.53 pp |
| Q2 2017 | 2017-06-30 | −35.75% | +164.21 pp |
| Q1 2017 | 2017-03-31 | −33.58% | +202.65 pp |
| Q4 2016 | 2016-12-31 | −53.86% | +184.03 pp |
| Q3 2016 | 2016-09-30 | −123.24% | +137.51 pp |
| Q2 2016 | 2016-06-30 | −199.96% | +206.86 pp |
| Q1 2016 | 2016-03-31 | −236.23% | +175.10 pp |
| Q4 2015 | 2015-12-31 | −237.89% | — |
| Q3 2015 | 2015-09-30 | −260.75% | — |
| Q2 2015 | 2015-06-30 | −406.82% | — |
| Q1 2015 | 2015-03-31 | −411.33% | — |
NovoCure ebitda margin trends
Over the last five fiscal years, NovoCure's ebitda margin decreased from 8.00% to −21.23%, a change of −29.23 percentage points. The latest reported quarter, Q2 2026, shows −3.41%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NovoCure source filings ↗Community posts
Novocure raises annual revenue and EBITDA targets as patient numbers grow
Novocure ($NVCR) lifted its 2026 revenue forecast to $736–$743 million from $710–$725 million and its adjusted EBITDA outlook to $24–$34 million from $0–$15 million. Third-quarter 2026 revenue increased 16% to $193.4 million, supported by 1 ...
